Swiss drugmaker Novartis predicted that the Australian government would not defend its nuclear medicine world technology ...

Lutetium-177-PSMA-617 (177Lu-PSMA-617), a type of targeted radiation therapy, is effective for men with advanced prostate cancer, even if they were previously treated with another radiation ...

The results from these pivotal trials have firmly positioned 177 Lu-PSMA-617 therapy within the standard therapeutic arsenal for mCRPC. However, questions remain regarding identifying which patients ...

In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...

Scientists from Tomsk Polytechnic University, in collaboration with their colleagues, supported by the federal Priority-2030 ...

The data compares favourably to published data on first-generation PSMA-targeted radioligand therapies. 1,2 The Phase 1 data shows that Lutetium (177 Lu) rhPSMA-10.1 Injection has high ratios for ...

In combination with the promising Phase 1 data for Lutetium (177 Lu ... important pharmacokinetic characteristics. Radiohybrid PSMA offers the potential for targeted treatment for men with ...

The data compares favourably to published data on first-generation PSMA-targeted radioligand therapies.1,2 The Phase 1 data shows that Lutetium (177Lu) rhPSMA-10.1 Injection has high ratios for ...

Phase 2 trial design will seek to maximise radiation doses to tumor and extend the duration of therapy, with first metastatic ...

Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.